AGL 38.09 Decreased By ▼ -0.07 (-0.18%)
AIRLINK 136.34 Increased By ▲ 2.15 (1.6%)
BOP 9.20 Increased By ▲ 0.35 (3.95%)
CNERGY 4.72 Increased By ▲ 0.03 (0.64%)
DCL 8.85 Increased By ▲ 0.18 (2.08%)
DFML 38.34 Decreased By ▼ -1.44 (-3.62%)
DGKC 85.45 Increased By ▲ 0.30 (0.35%)
FCCL 35.15 Increased By ▲ 0.25 (0.72%)
FFBL 76.21 Increased By ▲ 0.61 (0.81%)
FFL 12.66 Decreased By ▼ -0.08 (-0.63%)
HUBC 108.70 Decreased By ▼ -0.75 (-0.69%)
HUMNL 14.73 Increased By ▲ 0.63 (4.47%)
KEL 5.58 Increased By ▲ 0.18 (3.33%)
KOSM 7.96 Increased By ▲ 0.21 (2.71%)
MLCF 40.78 Decreased By ▼ -0.59 (-1.43%)
NBP 70.94 Increased By ▲ 1.24 (1.78%)
OGDC 195.25 Increased By ▲ 1.63 (0.84%)
PAEL 26.96 Increased By ▲ 0.75 (2.86%)
PIBTL 7.46 Increased By ▲ 0.04 (0.54%)
PPL 168.02 Increased By ▲ 4.17 (2.55%)
PRL 26.19 Decreased By ▼ -0.17 (-0.64%)
PTC 20.34 Increased By ▲ 0.87 (4.47%)
SEARL 92.75 Increased By ▲ 8.35 (9.89%)
TELE 7.84 Decreased By ▼ -0.15 (-1.88%)
TOMCL 35.49 Increased By ▲ 1.44 (4.23%)
TPLP 8.91 Increased By ▲ 0.19 (2.18%)
TREET 17.29 Increased By ▲ 0.11 (0.64%)
TRG 59.27 Decreased By ▼ -1.73 (-2.84%)
UNITY 31.02 Increased By ▲ 2.06 (7.11%)
WTL 1.37 No Change ▼ 0.00 (0%)
BR100 10,901 Increased By 125.5 (1.16%)
BR30 32,654 Increased By 420 (1.3%)
KSE100 101,357 Increased By 1274.6 (1.27%)
KSE30 31,488 Increased By 295 (0.95%)
Business & Finance

Novartis profits slide in Q1 on weak generic drugs

  • At $2 billion (1.7 billion euros), the bottom line fell 5.0 percent year-on-year in January-March, even as revenues grew 1.0 percent, to $12.4 billion.
Published April 27, 2021

ZURICH: Swiss pharma giant Novartis on Tuesday reported falling profits in the first quarter as its generic medicines unit Sandoz proved a drag on earnings.

At $2 billion (1.7 billion euros), the bottom line fell 5.0 percent year-on-year in January-March, even as revenues grew 1.0 percent, to $12.4 billion, the group said in a statement.

Driven by flagship drugs like heart medication Entresto, sales were up even in a tough comparison with last year's first quarter, when doctors, hospitals and patients stocked up as the first coronavirus lockdowns came into effect in much of the world.

But falling prices for generics "due to increasing competition" as well as the comparison with the early 2020 stocking-up effect drove currency-adjusted revenues at the Sandoz division down 13 percent.

This year also brought a "historically weak cough and cold season" undermining first-quarter demand, Novartis said.

Nevertheless, "we expect Sandoz performance to stabilise, in the near-term, after a challenging quarter," chief executive Vas Narasimhan said in the statement.

He added that he was confident for the group's outlook as "growth drivers and launches continued their strong momentum".

Novartis stuck to its forecasts of low- to mid-single-digit growth in currency-adjusted sales.

Comments

Comments are closed.